In a classic example of how basic toxicology leads to translational outcomes, follow-up studies demonstrated that an AHR inhibitor, Stemregulin-1, expands HSCs in vitro and that these expanded HSC populations shorten the recovery time in high dose chemotherapy-treated, stem cell-rescued cancer patients [194,195]. Here, AHR is linked to cancer.